These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 8369984

  • 1. Extracellular and intracellular action of clodronate in osteolytic bone diseases? A hypothesis.
    van Rooijen N.
    Calcif Tissue Int; 1993 Jun; 52(6):407-10. PubMed ID: 8369984
    [No Abstract] [Full Text] [Related]

  • 2. [Pharmacology of clodronate and its mechanism of action on bone resorption].
    Fleisch H.
    Bull Cancer; 1993 Jun; 80(10 Suppl):41-4. PubMed ID: 8081029
    [No Abstract] [Full Text] [Related]

  • 3. [Dichloromethylene diphosphonate in the treatment of lytic bone metastases].
    Chantraine A, Jung A, van Ouwenaller C, Donath A.
    Presse Med; 1984 Feb 25; 13(8):479-82. PubMed ID: 6230629
    [Abstract] [Full Text] [Related]

  • 4. Use of dichloromethylene diphosphonate in metastatic bone disease.
    Jung A, Chantraine A, Donath A, van Ouwenaller C, Turnill D, Mermillod B, Kitler ME.
    N Engl J Med; 1983 Jun 23; 308(25):1499-501. PubMed ID: 6222257
    [Abstract] [Full Text] [Related]

  • 5. Clodronate for osteolytic metastases due to breast cancer.
    Elomaa I, Blomqvist C, Porkka L, Holmström T, Taube T, Lamberg-Allardt C, Borgström GH.
    Biomed Pharmacother; 1988 Jun 23; 42(2):111-6. PubMed ID: 2971403
    [Abstract] [Full Text] [Related]

  • 6. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.
    Frith JC, Mönkkönen J, Auriola S, Mönkkönen H, Rogers MJ.
    Arthritis Rheum; 2001 Sep 23; 44(9):2201-10. PubMed ID: 11592386
    [Abstract] [Full Text] [Related]

  • 7. Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy.
    Elomaa I, Blomqvist C.
    Acta Oncol; 1995 Sep 23; 34(5):629-36. PubMed ID: 7546830
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New French studies of clodronate in cancer-induced osteolysis.
    Burki F.
    Bone; 1991 Sep 23; 12 Suppl 1():S35. PubMed ID: 1835399
    [No Abstract] [Full Text] [Related]

  • 10. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model.
    Ren W, Markel DC, Schwendener R, Ding Y, Wu B, Wooley PH.
    J Biomed Mater Res A; 2008 Jun 15; 85(4):1043-51. PubMed ID: 17937417
    [Abstract] [Full Text] [Related]

  • 11. Beneficial effects of oral clodronate in the management of malignant osteolysis and hypercalcaemia.
    Aranko K, Hanhijärvi H, Humphreys M, Drake J, Lawton WA.
    Bone; 1995 Feb 15; 16(2):275-8. PubMed ID: 7756058
    [No Abstract] [Full Text] [Related]

  • 12. [Value of Clodronate in the treatment of bone metastasis].
    Pouillart P, Beuzeboc P.
    Bull Cancer; 1991 Feb 15; 78(8):737-41. PubMed ID: 1834287
    [Abstract] [Full Text] [Related]

  • 13. Treatment of malignant hypercalcaemia with clodronate.
    Percival RC, Paterson AD, Yates AJ, Beard DJ, Douglas DL, Neal FE, Russell RG, Kanis JA.
    Br J Cancer; 1985 May 15; 51(5):665-9. PubMed ID: 3158326
    [Abstract] [Full Text] [Related]

  • 14. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.
    Frith JC, Mönkkönen J, Blackburn GM, Russell RG, Rogers MJ.
    J Bone Miner Res; 1997 Sep 15; 12(9):1358-67. PubMed ID: 9286751
    [Abstract] [Full Text] [Related]

  • 15. [Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].
    Szturz P, Jakubcová R, Adam Z, Klincová M, Krejcí M, Pour L, Zahradová L, Hájek R, Mayer J.
    Klin Onkol; 2011 Sep 15; 24(3):216-20. PubMed ID: 21717791
    [Abstract] [Full Text] [Related]

  • 16. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.
    Laakso M, Lahtinen R, Virkkunen P, Elomaa I.
    Br J Haematol; 1994 Aug 15; 87(4):725-9. PubMed ID: 7986713
    [Abstract] [Full Text] [Related]

  • 17. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.
    O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA.
    J Clin Oncol; 1995 Apr 15; 13(4):929-34. PubMed ID: 7707121
    [Abstract] [Full Text] [Related]

  • 18. Use of clodronate in multiple myeloma.
    Jantunen E, Lahtinen R, Laakso M.
    Leuk Lymphoma; 1995 Oct 15; 19(3-4):207-11. PubMed ID: 8535211
    [Abstract] [Full Text] [Related]

  • 19. [Osteolytic metastases of breast cancer and biphosphonates].
    Lortholary A, Alleaume C, Pein F, Larra F.
    Rev Med Interne; 1992 Oct 15; 13(3):238-42. PubMed ID: 1410908
    [Abstract] [Full Text] [Related]

  • 20. The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron.
    Mönkkönen J, Heath TD.
    Calcif Tissue Int; 1993 Aug 15; 53(2):139-46. PubMed ID: 8402323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.